Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Lapatinib + Patritumab |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Lapatinib | Tykerb | Lapatinib Ditosylate | EGFR Inhibitor (Pan) 62 HER2 Inhibitor 42 | Tykerb (lapatinib) reversibly inhibits ERBB2 (HER2) and EGFR, resulting in decreased downstream signaling and potentially leading to reduced tumor growth (PMID: 22477724). Tykerb (lapatinib) is FDA approved for ERBB2 (HER2)-positive (overexpressing) breast cancer (FDA.gov). |
Patritumab | U3-1287|AMG-888 | HER3 (ERBB3) Antibody 23 | Patritumab (U3-1287) is a monoclonal antibody that targets HER3 and inhibits ligand binding, potentially resulting in decreased activation of downstream signaling and reduced tumor growth (PMID: 24442032, PMID: 31648099). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|